Insulin lispro: A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus

Drugs

Volumn 54, Issue 4, 1997, Pages 597-614

  Wilde, Michelle I ^a   McTavish, Donna ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A; HUMAN INSULIN; HYPERGLYCEMIC AGENT; INSULIN LISPRO; INSULIN RECEPTOR; INSULIN ZINC SUSPENSION; LYSINE; PROLINE; RECOMBINANT HUMAN INSULIN;

CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; INSULIN ALLERGY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIPODYSTROPHY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; POSTPRANDIAL STATE; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030690552     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754040-00006     Document Type: Review

References (82)

1. DiMarchi RD, Chance RH, Long HB, et al. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Res 1994; 41 Suppl 2: 93-6
2. B29-human insulin. Structure 1995; 3: 615-22
3. Barnett AH, Owens DR. Insulin analogues. Lancet 1997; 349: 47-51
4. Holleman F, Hoekstra JBL. Insulin lispro. N Engl J Med 1997; 337: 176-83
5. Brems DN et al. Altering the association properties of insulin by amino acid replacement. Protein Eng 1992; 6: 527-33
6. Jehle PM, Fussgaenger RD, Kunze U, et al. The human insulin analog insulin lispro improves insulin binding on circulating monocytes of intensively treated insulin-dependent diabetes mellitus patients. J Clin Endocrinol Melab 1996 Jun; 81: 2319-27DEC
7. Jehle PM, Fussgänger RD, Seibold A, et al. Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus. Int J Clin Pharmacol Ther 1996: 34 (11): 498-503
8. Eli Lilly and company. Humalog®. Insulin lispro injection (rDNA origin). Indianapolis, 1996
9. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994 Mar; 43: 396-402
10. Woodworth J, Howey D, Bowsher R, et al. [Lys(B28). Pro(B29)] human insulin (K): dose-ranging vs humulin R (H) [abstract]. Diabetes 1993 May; 42 Suppl. 1: 54A
11. Trautmann ME. Effect of the insulin analogue [LYS(B28). PRO(B29)] on blood glucose control. Horm Metab Res 1994 Dec; 26: 588-90
12. Torlone E, Fanelli C, Rambotti AM, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulalion following subcutaneous injection of the monomeric insulin analogue [Lys(B28).Pro(B29)] in IDDM. Diahctologia 1994 Jul; 37: 713-20
13. Bruttomesso D, Pianta A, Valerio A, et al. Fast acting insulin analog (Lispro) improves glucose tolerance of NIDDM by inhibiting hepatic glucose production [abstract]. Diabetes 1996 May; 45 Suppl. 2: 140
14. Vignati L, Anderson JH, Szwast S, et al. Twice daily lispro results in less glucose variability compared to human regular insulin. Diabetologia 1995; 38 Suppl. 1: A191
15. Heinemann L, Heise T, Wahl LC, et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28). Pro(B29)] human insulin. Diabetic Mod 1996 Jul; 13: 625-9
16. Gulli G, Galati E. Poggi G, et al. [Lys(B28), Pro(B29)]-human insulin vs regular human insulin: quantitation of glucose disposal in NIDD humans during intravenous infusion [abstract]. Diabetes 1996 May; 45 Suppl. 2: 73A
17. Schernthaner G, Wein W, Sandholzer K, et al. Postprandial insulin lispro - a new option in type-I diabetic patients [abstract no. 0388]. Diabetes 1997; 46 Suppl. 1: 98A
18. Strachan MWJ, Frier BM. Insulin lispro in IDDM. Scott Med J 1997; 42: 25
19. Stiller R, Gudat U, Pfütner A, et al. Postprandial treatment with lispro insulin. Diabetes Metab Rev 1997; 23: 232-3
20. Burge MR, Waters DL, Holcombe JH, et al. Prolonged efficacy of short acting insulin lispro in combination with human ultralente in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82 (3): 920-4
21. Jacobs MAJM, Salobir B, Popp-Snijders C, et al. Counter-regulatory hormone responses and symptoms during hypoglycuemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin lisprol in healthy male volunteers. Diabetic Med 1997; 14: 248-57
22. Fineberg NS, Fineberg SE, Anderson JH, et al. Immunologic effects of insulin lispro [Lys(B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996 Dec: 45: 1750-4
23. Fineberg SE, Fineberg NS, Anderson JH, et al. Does the use of short acting (LysPro) human insulin in insulin naive patients augment the insulin immune response or differ between type I and type II patients? [abstract). Diabetes 1995 May; 44 Suppl. I: 231A
24. Roach P, Varshavsky JA, Gantner K, et al. Insulin antibody formation during treatment with human insulin or insulin lispro does not affect insulin dose requirements (abstract). Diabetes 1996 May; 45 Suppl. 2: 261A
25. Lahtela JT, Knip M, Paul R, et al. Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. Diabetes Care 1997; 20 (1): 71-3
26. Henrichs HR, Unger H, Trautmann ME, et al. Severe insulin resistance treated with insulin lispro [letter]. Lancet 1996; 348: 1248
27. Braimon J, O'Brien M, Kaulbach H, et al. The insulin analog lispro effectively treats anti-insulin antibody mediated insulin resistance [abstract]. Diabetes 1996 May; 45 Suppl. 2: 185A
28. Jehle PM, Holl RW, Fussgänger RD, et al. Correlation of insulin resistance in type-II diabetes with reduced binding affinity of insulin receptors [abstract no. 539]. Diabetologica 1995; 38 Suppl. 1: A139
29. Caixàs A. érez: A. Castellvi A, et al. Effect of intensive therapy with insulin lispro on VLDL composition in type 1 diabetes [bstract]. Diabetologia 1994 Aug; 37 Suppl. 1: A147
30. Pérez A, Caixàs A, Payés A, et al. Insulin lispro and regular insulin have a similar effect on lipolytic activities and VLDL composition in NIDDM [abstract]. Diabetologia 1994 Aug; 37 Suppl. 1: A168
31. Perez A, Caixas A, Payes A, et al. Cholesteryl ester transfer protein and lipolitic activities in NIDDM and IDDM: effects of intensive insulin therapy with lispro and regular insulin [abstract]. Diabetes 1995 May; 44 Suppl. 1: I47A
32. Reviriego J, Perez A, Caixas A, et al. Lack of change of Lp(a) levels under intensified conventional therapy with Insulin Lispro or Regular Insulin [abstract]. 15th International Diabetes Federation Congress; 1994 Nov 6-11: Kobe, 255
33. Garg SK, Carmain JA, Braddy KC, et al. Pre-meal insulin analogue insulin lispro vs Humulin® R insulin treatment in young subjects with type 1 diabetes. Diabetic Med 1996 Jan; 13: 47-52
34. Zimmermann JL, Truex LL. A 12-month chronic toxicity study of LY275585 (human insulin analogue) administered subcutaneously to Fischer 344 rats. Intl J Tox (In press)
35. Jacobs MAJM, Kanc K, Keulen E, et al. The metabolic efficacy of Lispro human insulin analogue in a multiple injection (MIT) regimen [abstract]. Neth J Med 1995 May; 46: A37-8
36. Jacobs MAJM, Keulen E, Kanc K, et al. Energy expenditure during pre-prandial administration of Lispro insulin analogue in IDDM patients [abstract]. Neth J Med 1995 Dec; 47: A60
37. Jacobs MAJM, Keulen ETP, Kanc K, et al. Metabolic efficacy of preprandial administration of Lys(B28),Pro(B29) human insulin analog in IDDM patients. Diabetes Care 1997; 20 (8): 1279-86
38. Chiasson J-L, Pacaud D, Bourque J, et al. Effect of insulin lispro vs regular insulin on postprandial glucose metabolism [in French] [abstract]. Diabete Metab 1996 Mar; 22 Suppl.: 28
39. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995 Oct; 58: 459-69
40. Pöyry K, Tuominen JA, Kostamo E, et al. Sauna enhances the absorption of short-acting insulin analogue [abstract]. Eur J Endocrinol 1995 Apr; 132 Suppl. 1: 22
41. Anderson Jr JH, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997 Feb; 46: 265-70
42. Anderson Jr JH, Brunelle RL, Keohane R et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycaemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997 Jun; 157: 1249-55
43. Anderson Jr JH, Brunelle RL, Koivisto VA, et al. Improved mealtime treatment of diabetes mellilus using an insulin analogue. Clin Ther 1997; 19 (10): 62-72
44. Crowley M, Alexander W, Cassar DJ, et al. Insulin Lispro improves postprandial blood glucose control in type 1 and type 2 diabetes without increasing the frequency of hypoglycaemia [abstract]. Diabetic Med 1995; 12 Suppl. 2: S33
45. Pfützner A, Küstner E. Forst T, et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 1996; 104 (1): 25-30
46. Rowe R, Anderson JH, Gale E. A double-blind comparison of insulin lispro and regular insulin in patients on a multiple injection regimen [abstract]. Diabetes 1996 May: 45 Suppl. 2: 71A
47. Vignati L, Brunelle RL. Treatment of 722 patients with type II diabetes with insulin lispro in a 6 month crossover study [abstract]. Diabetes 1995 May; 44 Suppl. 1: 229A
48. Vignati L, Anderson JH, Brunelle RL, et al. Improvement of glycemic control with the rapidly absorbed lispro insulin analog in type I diabetes [abstract]. Diabetologia 1994 Aug: 37 Suppl. 1: A78
49. Trautmann M, Brunelle R, Koivisto V, et al. Reduction of postprandial glucose rise by insulin lispro is independent from premeal glucose values [abstract]. Diabetes 1996 May; 45 Suppl. 2: 121A
50. Anderson JH, Vignati L, Brunelle RL, et al. Therapy of type II diabetes with insulin lispro, a fast-acting human insulin analog [abstract]. 15th International Diabetes Federation Congress; 1994 Nov 6-11; Kobe, 254
51. Tuominen JA, Karonen S-L, Melamies L, et al. Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 1995 Jan; 38: 106-11
52. Holcombe J, Zalani S, Arora V, et al. Comparative study of insulin lispro and regular insulin in 481 adolescents with type I diabetes. Diabetes 1997; 46 Suppl. 1: 329A
53. Pampanelli S, Torlone E, Lalli C, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic β-cell function. Diabetes Care 1995 Nov; 18: 1452-9
54. Feinglos MN, Lane JD, ThackerCH, et al. Pre-prandial insulin lispro improves glucose control in patients with secondary sulfonylurea failure [abstract]. Diabetes 1996 May; 45 Suppl. 2: 286A
55. Ross S, Zinman B, Campos R, et al. Effectiveness and safety of lispro in the management of patients with type II diabetes. Diabetes 1997; 46 Suppl. 1: 329A
56. B29-human insulin analog and human regular insulin in the correction of incidental hyperglycemia [abstract]. Diabetes 1996 May; 45 Suppl. 2: 288A
57. Zinman B, Chiasson JL, Tildesley H, et al. Insulin Lispro in CSII: results of a double-blind, cross-over study [abstract]. Diabetes 1996 May; 45 Suppl. 2: 28A
58. Pfützner A, Renner R, The German Humalog CSII Study Group. CSII therapy with insulin pumps using insulin lispro [abstract no. 0133]. Diabetes 1997: 46 Suppl. 1: 34A
59. Bode B, Steed R, Davidson P. Continuous subcutaneous insulin infusion (CSII): a study comparing lispro to regular human insulin [abstract no. 0167]. Diabetes 1997; 46 Suppl. 1: 43A
60. Renard E, Vague V, Finget M, et al. SC infusion of insulin Lispro vs human regular insulin by portable pumps: significant improvement of HbA lc and blood glucose stability under insulin Lispro [abstract no. 0605]. Diabetes 1997; 46 Suppl. 1: 157A
61. Schmauss S, Landgraf R. Cross-over insulin pump study with human insulin analogue [Lys(B28),Pro(B29)[ [abstract no. 1393]. Diabetologia 1997; 40 Suppl. 1: A354
62. Desmet M, Rutters A, Schmitt H, et al. [Lys (B28), Pro(B29)] human insulin (LysPro): patients treated with LysPro vs hu- man regular insulin - quality of life assessment (QOL) [abstract]. Diabetes 1994; 43 Suppl. 1: 167A
63. Kotsanos JG, Vignati L, Huster W, et al. Health-related qualityof-life results from multinational clinical trials of insulin lispro. Diabetes Care 1997; 20 (6): 948-58
64. Howorka K, Pumprla J, Schlusche C, et al. Insulin lispro changes treatment satisfaction under flexible functional insulin treatment [abstract no. 1390]. Diabetologia 1997; 40 Suppl. 1: A353
65. Brunelle RL, Llewelyn J, Vignati L, et al. Humalog reduces the incidence of severe hypoglycemia in IDDM patients [abstract no. 1386]. Diabetologia 1997; 40 Suppl.: A352
66. Anderson J, Symanowski S, Brunelle R. Safety of [Lys(B28), Pro(B29)] human insulin analog in long-term clinical trials |abstract|. Diabetes 1994; 43 Suppl. 1: 61A
67. Brunelle RL, Symanowski S, Anderson Jr JH, et al. Less nocturnal hypoglycemia with insulin lispro in comparison to human regular [abstract]. Diabetes 1995 May; 44 Suppl. 1: 111 A
68. Heller SR, Amiel SA, Janes J. Hypoglycaemiaduring intensive insulin therapy: a comparison of lispro and regular insulin [abstract no. 0581]. Diabetes 1997; 46 Suppl. 1: 151A
69. Holcombe J, Zalani S, Arora V, et al. Insulin lispro (LP) results in less nocturnal hypoglycemia compared with regular human insulin in adolescents with type I diabetes [abstract no. 0402]. Diabetes 1997; 46 Suppl.: 103A
70. Burge MR, Castillo KR, Schade DS. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care 1997; 20 (2): 152-5
71. Brunelle RL, Anderson JH, Vignati L. Decreased rate of hypoglycemia in association with improved metabolic control with insulin lispro [abstract no. 300]. Diabetologia 1994 Aug; 37 Suppl. 1: A78
72. Bastyr EJIII, Kotsanos J, Vignati L, et al. Insulin lispro (LP) reduces hypoglycemia rate in persons with type II diabetes at high risk for hypoglycemia [abstract]. Diabetes 1996 May; 45 Suppl. 2: 56A
73. Symanowski SM, Brunelle RJ, Anderson JH. A new technique of population subgroup analysis to evaluate the safety of insulin lispro [abstract]. 15th International Diabetes Federation Congress; 1994 Nov 6-11: Kobe, 120
74. Pfützner A, Gudal U, Trautmann ME. Longterm use of insulin lispro in intensive insulin therapy [abstract]. Diabetes 1996 May; 45 Suppl. 2: 286A
75. Lougheed WD, Zinman B, Strack TR, et al. Stability of insulin lispro in insulin infusion systems. Diabetes Care 1997; 20 (7): 1061-5
76. Herter CD. Insulin lispro: the next step. Clinical Diabetes 1997 Mar/Apr: 51-6
77. Ebeling P, Jansson P-A, Smith U, et al. Strategies toward improved control during insulin lispro therapy in IDDM. Diabetes Care 1997; 20 (8): 1287-9
78. Del Sindaco P, Ciofetta M, Lalli C, et al. Importance of basal insulin to improve control without increasing hypoglycaemia in intensively treated IDDM using a short-acting insulin analog at meals [abstract no. 1384]. Diabetologica 1997; 40 Suppl. 1: A352
79. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329: 977-86
80. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17
81. Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18 (11): 1468-78
82. Lispro, a rapid-onset insulin. Med Lett Drugs Ther 1996; 38 (986): 97-8